Profile data is unavailable for this security.
About the company
ChengDu Sheng Nuo Biotec Co Ltd is a China-based company mainly engaged in the research and development of peptide active pharmaceutical ingredients (APIs) and preparation products. The Company's main business includes independent research and development, production and sales of peptide APIs and preparations, providing pharmaceutical research services for peptide innovative drugs, customized production services for peptide products and transfer services for peptide drug production technology for domestic and foreign pharmaceutical companies, providing original equipment manufacture processing of small molecule chemical drug levosimendan preparations and levosimendan API production, export and sales business. The Company's products target areas including immunity, digestive tract, antiviral, obstetrics and gynecology, diabetes, cardiovascular and cerebrovascular, rare diseases, orthopedics and others. The Company mainly conducts its business in domestic and foreign markets.
- Revenue in CNY (TTM)481.63m
- Net income in CNY92.49m
- Incorporated2001
- Employees1.13k
- LocationChengDu Sheng Nuo Biotec Co LtdNo. 98, Da'an Road, Dayi CountyCHENGDU 611330ChinaCHN
- Phone+86 2 888203615
- Fax+86 2 888203668
- Websitehttps://www.snbiopharm.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ningbo Menovo Pharmaceutical Co Ltd | 1.24bn | 20.30m | 2.92bn | 2.35k | 153.22 | 1.34 | -- | 2.36 | 0.087 | 0.087 | 5.70 | 9.92 | 0.267 | 1.18 | 4.91 | 525,730.80 | 0.5164 | 4.94 | 0.7951 | 7.83 | 29.01 | 35.39 | 1.93 | 13.71 | 0.7203 | 4.44 | 0.4199 | 10.78 | -16.51 | 7.46 | -96.58 | -34.53 | -6.03 | -32.54 |
| Henan Taloph Pharmaceutical Stock Co Ltd | 1.97bn | 89.38m | 2.94bn | 2.35k | 33.87 | 1.87 | -- | 1.50 | 0.1515 | 0.1515 | 3.39 | 2.74 | 0.5571 | 2.93 | 2.06 | 836,256.80 | 2.67 | 0.272 | 5.80 | 0.4981 | 27.64 | 27.97 | 4.79 | 0.5501 | 0.8146 | 2.65 | 0.3911 | 28.70 | 5.57 | 11.62 | 160.32 | -- | -8.27 | -- |
| GuiZhou YiBai Pharmaceutical Co., Ltd. | 2.40bn | -235.62m | 2.95bn | 5.51k | -- | 1.12 | -- | 1.23 | -0.2975 | -0.2975 | 3.03 | 3.34 | 0.5288 | 1.52 | 13.04 | 435,209.10 | -5.39 | 0.8648 | -6.97 | 1.18 | 61.81 | 74.87 | -10.19 | 1.45 | 1.36 | -9.98 | 0.2375 | 216.36 | 3.12 | -6.19 | 124.25 | -- | -16.51 | -- |
| Shanghai MicuRx Pharmaceutical Co Ltd | 120.07m | -467.96m | 3.11bn | 205.00 | -- | 5.48 | -- | 25.92 | -0.7142 | -0.7142 | 0.1833 | 0.8664 | 0.1067 | 0.623 | 4.76 | 585,689.70 | -41.57 | -- | -45.49 | -- | 81.88 | -- | -389.75 | -- | 6.43 | -- | 0.3488 | -- | 88.31 | -- | -91.16 | -- | -- | -- |
| ChengDu Sheng Nuo Biotec Co Ltd | 481.63m | 92.49m | 3.14bn | 1.13k | 33.83 | 3.42 | -- | 6.51 | 0.8279 | 0.8279 | 4.31 | 8.20 | 0.3401 | 0.862 | 3.96 | 426,977.70 | 6.52 | 7.47 | 8.67 | 9.44 | 59.92 | 70.52 | 19.17 | 15.82 | 0.8466 | 13.35 | 0.32 | 21.83 | 9.93 | 9.37 | 9.08 | 18.69 | 54.71 | -- |
| Zhejiang Shapuaisi Pharmaceutical Co Ltd | 540.27m | -72.66m | 3.18bn | 1.39k | -- | 1.88 | -- | 5.90 | -0.1922 | -0.1922 | 1.44 | 4.46 | 0.2581 | 2.94 | 13.86 | 390,086.00 | -3.48 | -0.7573 | -4.00 | -0.8713 | 51.90 | 58.02 | -13.49 | -2.45 | 0.8094 | -- | 0.1284 | -- | 17.37 | 1.21 | -43.23 | -- | 30.36 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Rongtong Fund Management Co., Ltd.as of 30 Jun 2024 | 3.57m | 5.39% |
| China Fund Management Co., Ltd.as of 30 Jun 2024 | 2.63m | 3.96% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2024 | 2.45m | 3.69% |
| Golden Trust Sinopac Fund Management Co., Ltd.as of 30 Jun 2024 | 1.84m | 2.78% |
| Great Wall Fund Management Co., Ltd.as of 30 Jun 2024 | 1.45m | 2.18% |
| HuaAn Fund Management Co., Ltd.as of 30 Jun 2024 | 1.44m | 2.18% |
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 1.35m | 2.05% |
| China Merchants Fund Management Co., Ltd.as of 30 Jun 2024 | 872.74k | 1.32% |
| China International Capital Corp. HK Asset Management Ltd.as of 30 Jun 2024 | 812.68k | 1.23% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2024 | 395.42k | 0.60% |
